247 related articles for article (PubMed ID: 37355297)
41. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?
Bavishi C; Bangalore S; Messerli FH
Prog Cardiovasc Dis; 2016; 59(3):253-261. PubMed ID: 27777044
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
[TBL] [Abstract][Full Text] [Related]
43. Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
Li SM; He WB; Chen J; Cai QQ; Huang FF; Zhang K; Wang JF; Liu X; Huang H
Atherosclerosis; 2018 Feb; 269():35-41. PubMed ID: 29258005
[TBL] [Abstract][Full Text] [Related]
44. Epidemiology of hyperkalemia in chronic kidney disease.
Belmar Vega L; Galabia ER; Bada da Silva J; Bentanachs González M; Fernández Fresnedo G; Piñera Haces C; Palomar Fontanet R; Ruiz San Millán JC; de Francisco ÁLM
Nefrologia (Engl Ed); 2019; 39(3):277-286. PubMed ID: 30898450
[TBL] [Abstract][Full Text] [Related]
45. Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.
Yoshida S; Ishizawa K; Ayuzawa N; Ueda K; Takeuchi M; Kawarazaki W; Fujita T; Nagase M
Clin Exp Nephrol; 2014 Aug; 18(4):593-9. PubMed ID: 24154707
[TBL] [Abstract][Full Text] [Related]
46. Angioedema related to Angiotensin inhibitors.
Knecht SE; Dunn SP; Macaulay TE
J Pharm Pract; 2014 Oct; 27(5):461-5. PubMed ID: 25124378
[TBL] [Abstract][Full Text] [Related]
47. Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study.
Tylicki L; Jakubowska A; Lizakowski S; Świetlik D; Rutkowski B
J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):145-52. PubMed ID: 25324423
[TBL] [Abstract][Full Text] [Related]
48. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
49. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
50. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
Ruggenenti P; Cravedi P; Remuzzi G
Nat Rev Nephrol; 2010 Jun; 6(6):319-30. PubMed ID: 20440277
[TBL] [Abstract][Full Text] [Related]
51. Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction.
Loutradis C; Price A; Ferro CJ; Sarafidis P
J Hum Hypertens; 2021 Jun; 35(6):499-509. PubMed ID: 33654237
[TBL] [Abstract][Full Text] [Related]
52. Chronic kidney disease and albuminuria in arterial hypertension.
Leoncini G; Viazzi F; Pontremoli R
Curr Hypertens Rep; 2010 Oct; 12(5):335-41. PubMed ID: 20694530
[TBL] [Abstract][Full Text] [Related]
53. Discontinuation of RAAS Inhibition in Children with Advanced CKD.
van den Belt SM; Heerspink HJL; Kirchner M; Gracchi V; Thurn-Valsassina D; Bayazit AK; Niemirska A; Canpolat N; Kaplan Bulut I; Azukaitis K; Duzova A; Bacchetta J; Shroff R; Paripovic D; Özçakar ZB; Fidan K; Erdogan H; Gellermann J; Wühl E; de Zeeuw D; Melk A; Querfeld U; Schaefer F
Clin J Am Soc Nephrol; 2020 May; 15(5):625-632. PubMed ID: 32253275
[TBL] [Abstract][Full Text] [Related]
54. Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.
Petrykiv SI; Laverman GD; Persson F; Vogt L; Rossing P; de Borst MH; Gansevoort RT; de Zeeuw D; Heerspink HJL
Clin J Am Soc Nephrol; 2017 Nov; 12(11):1804-1813. PubMed ID: 29021336
[TBL] [Abstract][Full Text] [Related]
55. [New aspects of pharmacological nephroprotection].
Beimler J
Inn Med (Heidelb); 2022 Nov; 63(11):1200-1207. PubMed ID: 35380212
[TBL] [Abstract][Full Text] [Related]
56. Aldosterone blockade as an alternative renin-angiotensin-aldosterone system blocking agent in cases of treatment associated anemia.
Avasare RS; Appel GB; Bomback AS
Clin Nephrol; 2014 May; 81(5):350-4. PubMed ID: 23211336
[TBL] [Abstract][Full Text] [Related]
57. The renin-angiotensin-aldosterone system blockade and arterial stiffness in renal transplant recipients - a cross-sectional prospective observational clinical study.
Heleniak Z; Illersperger S; Brakemeier S; Bach P; Dębska-Ślizień A; Budde K; Halleck F
Acta Biochim Pol; 2020 Dec; 67(4):613-622. PubMed ID: 33332078
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Lambers Heerspink HJ
Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
[TBL] [Abstract][Full Text] [Related]
59. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
[TBL] [Abstract][Full Text] [Related]
60. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis.
Zhao HJ; Li Y; Liu SM; Sun XG; Li M; Hao Y; Cui LQ; Wang AH
Ren Fail; 2016 Jul; 38(6):849-56. PubMed ID: 27055479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
